Toggle light / dark theme

Bio-Printing Complex Human Tissues & Organs — Dr. Anthony Atala, MD — Director, Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Wake Forest University.


Dr. Anthony Atala, MD, (https://school.wakehealth.edu/Faculty/A/Anthony-Atala) is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of Urology.

A practicing surgeon and a researcher in the area of regenerative medicine, fifteen applications of technologies developed Dr. Atala’s laboratory have been used clinically. He is Editor of 25 books and 3 journals, has published over 800 journal articles, and has received over 250 national and international patents. Dr. Atala was elected to the Institute of Medicine of the National Academies of Sciences, to the National Academy of Inventors as a Charter Fellow, and to the American Institute for Medical and Biological Engineering.

Dr. Atala is a recipient of the US Congress funded Christopher Columbus Foundation Award, bestowed on a living American who is currently working on a discovery that will significantly affect society; the World Technology Award in Health and Medicine, for achieving significant and lasting progress; the Edison Science/Medical Award for innovation, the R&D Innovator of the Year Award, and the Smithsonian Ingenuity Award for Bioprinting Tissue and Organs. Dr. Atala’s work was listed twice as Time Magazine’s Top 10 medical breakthroughs of the year, and once as one of 5 discoveries that will change the future of organ transplants. He was named by Scientific American as one of the world’s most influential people in biotechnology, by U.S. News & World Report as one of 14 Pioneers of Medical Progress in the 21st Century, by Life Sciences Intellectual Property Review as one of the top key influencers in the life sciences intellectual property arena, and by Nature Biotechnology as one of the top 10 translational researchers in the world.

Dr. Atala has led or served several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, the National Institutes of Health Bioengineering Consortium, and the National Cancer Institute’s Advisory Board. He is a founding member of the Tissue Engineering Society, Regenerative Medicine Foundation, Regenerative Medicine Manufacturing Innovation Consortium, Regenerative Medicine Development Organization, and Regenerative Medicine Manufacturing Society.

TABLE OF CONTENTS —————
0:00–21:02 : Introduction (Meaning of Life)
21:03–46:14 CHAPTER 1: Transhumanism and Life Extension.

TWITTER https://twitter.com/Transhumanian.
PATREON https://www.patreon.com/transhumania.
BITCOIN 14ZMLNppEdZCN4bu8FB1BwDaxbWteQKs8i.
ETHEREUM 0x1f89b261562C8D4C14aA01590EB42b2378572164
LITECOIN LdB94n8sTUXBto5ZKt82YhEsEmxomFGz3j.

#1 ) THE GENETIC PATHWAY

46:15–58:52 CHAPTER 2 : Biological Aging a. “Programmed Cell Death” Theory of Aging b. “Intercellular Competition” Theory of Aging c. “Antagonistic Pleiotropy” Theory of Aging.

#2 ) THE CYBERNETIC PATHWAY

58:53–1:12:26 CHAPTER 3 : Cyborgs.
1:12:27–1:24:35 CHAPTER 4 : Artiforgs.
1:24:36–1:41:10 CHAPTER 5 : Prosthetics.
1:41:11–2:00:44 CHAPTER 6 : Bionics.

The company is developing novel therapeutics targeting aging in humans and dogs by using genetically modified adeno-associated virus (AAV) vectors to deliver copies of the SIRT6 gene variant found in centenarians. SIRT6 has already been shown to have significant capabilities to repair DNA damage, and Genflow’s aim is to show that it can also improve healthspan and, potentially, increase lifespan. “Our business model is to develop our lead compound, GF-1002, that has already yielded encouraging pre-clinical results,” Leire told us. “We are currently undertaking pre-clinical trials which are expected to take approximately two years.


SIRT6 targeting longevity biotech announces intention to float on the London Stock Exchange, with IPO later this month.

Sinclair’s first episode. Enjoy.


In this episode, Dr. David Sinclair and co-host Matthew LaPlante discuss why we age. In doing so, they discuss organisms that have extreme longevity, the genes that control aging (mTOR, AMPK, Sirtuins), the role of sirtuin proteins as epigenetic regulators of aging, the process of “ex-differentiation” in which cells begin to lose their identity, and how all of this makes up the “Information Theory of Aging”, and the difference between “biological age” and “chronological age” and how we can measure biological age through DNA methylation clocks.

Thank you to our sponsors:
Athletic Greens — https://athleticgreens.com/sinclair.
InsideTracker — https://insidetracker.com/sinclair.
Levels — https://levels.link/sinclair.

Our Patreon page:
https://www.patreon.com/davidsinclair.

Lifespan book:
https://amzn.to/3sUqurT

Dr. David Sinclair Social:
Instagram — https://www.instagram.com/davidsinclairphd.
Twitter — https://twitter.com/davidasinclair.
Facebook — https://www.facebook.com/davidsinclairphd.

Matthew LaPlante’s Social:
Twitter — https://twitter.com/mdlaplante.

Timestamps:
00:00:00 Introduction.
00:03:14 Goal of the Lifespan Podcast.
00:07:11 Acknowledgement of Sponsors.
00:10:45 Aging is a Controllable Process that can be Slowed & Reversed.
00:16:42 Organisms with Extreme Longevity.
00:21:47 Genes that Regulate Aging: mTOR, AMPK, Sirtuins.
00:21:55 mTOR & Rapamycin.
00:24:33 AMP-activated protein kinase (AMPK) & Metformin.
00:30:57 Sirtuin Proteins as Epigenetic Regulators of Aging.
00:35:33 Ex-Differentiation.
00:43:30 Measuring Aging — Biological Age vs. Chronological Age.
00:49:30 “No Law That Says We Have To Age“
00:50:33 Episode Summary & Key Takeaways — Why Do We Age?
00:54:00 Information Theory of Aging.
00:57:59 Aging is a Medical Condition.
01:01:00 Aging Myths — Telomeres & Antioxidants.
01:01:55 Options for Subscription and Support.

DNA damage is constantly occurring in cells, either due to external sources or as a result of internal cellular metabolic reactions and physiological activities. Accurate repair of such DNA damages is critical to avoid mutations and chromosomal rearrangements linked to diseases including cancer, immunodeficiencies, neurodegeneration, and premature aging.

A team of researchers at Massachusetts General Hospital and the National Cancer Research Centre have identified a way to repair genetic damage and prevent DNA alterations using machine learning techniques.

The researchers state that it is possible to learn more about how cancer develops and how to fight it if we understand how DNA lesions originate and repair. Therefore, they hope that their discovery will help create better cancer treatments while also protecting our healthy cells.

Down syndrome is the most common genetic disorder, impacting about 1 in 700 newborns around the world. At some point during their first hours and days of embryonic development, their dividing cells fail to properly wriggle a chromosome pair away from each other, leaving an extra copy where it shouldn’t be. Although scientists have known for more than six decades that this extra copy of chromosome 21 causes the cognitive impairment people with Down syndrome experience, exactly how it happens remains a matter of debate.


But in recent years, scientists using new RNA sequencing techniques to study cells from pairs of twins — one with Down syndrome and one without — have repeatedly turned up a curious pattern. It wasn’t just the genes on chromosome 21 that had been cranked way up in individuals with Down syndrome. Across every chromosome, gene expression had gone haywire. Something else was going on.

On Thursday, a team from the Massachusetts Institute of Technology reported in Cell Stem Cell that it may have found a surprising culprit: senescent cells, the same types implicated in many diseases of aging. The study was small and preliminary, and some experts want to see it replicated in samples from more individuals before buying into its interpretations. But they are nevertheless intriguing.

They say ‘I believe in nature. Nature is harmonious’. Every big fish is eating every smaller fish. Every organ is fighting constantly invading bacteria. Is that what you mean by harmony? There are planets that are exploding out there. Meteorites that hit another and blow up. What’s the purpose of that? What’s the purpose of floods? To drown people? In other words, if you start looking for purpose, you gotta look all over, take in the whole picture. So, man projects his own values into nature. — Jacque Fresco (March 13, 1916 — May 18, 2017)

When most of us use the word ‘nature‘, we really don’t know much about it in reality. — Ursa.

Unlocking The Secrets Of Salamander Regeneration For Regenerative Therapies — Dr. Maximina Yun, Ph.D., CRTD / Center for Regenerative Therapies TU Dresden, Technische Universität Dresden.


Dr. Maximina Yun, Ph.D. (https://tu-dresden.de/cmcb/crtd/forschungsgruppen/crtd-forschungsgruppen/yun/group-leader) is Research Group Leader at the Center for Regenerative Therapies Dresden (CRTD), Technical University Dresden, jointly affiliated with Max Planck Institute for Molecular Cell Biology and Genetics (MPI-CBG).

Dr. Yun and her group (https://tu-dresden.de/cmcb/crtd/forschungsgruppen/crtd-forschungsgruppen/yun) study the cellular and molecular basis of regeneration of complex structures with the help of salamanders (like newts and axolotls) and these vertebrates exceptional regenerative abilities, which in contrast to humans, are capable of regenerating complex tissues, and even entire organs, to a remarkable extent. Therefore, they offer unique insights into what molecular mechanisms must be in place for achieving quasi-perfect regeneration.

Research in the Yun group focuses on three main areas: describing cellular and molecular mechanisms driving regeneration (Mechanisms underlying the plasticity of the differentiated state), their connection with cellular aging (Role and regulation of senescence in regeneration), and the role that the immune system plays in regenerative context.

The research in the Yun group combines advanced molecular biology methods with state-of-the-art microscopy. Most recently the group has established Salamander-Eci, a novel method that enables the three-dimensional visualization of salamander tissues for a more comprehensive understanding of regenerative processes.

Dr. Yun received her Ph.D. in Biological Sciences from MRC-Laboratory of Molecular Biology of Cambridge / Cambridge University, UK, and did her Postdoctoral Research at the Institute of Structural and Molecular Biology, University College London, UK; Dr. Yun also has a BSc in Biological Sciences from University of Buenos Aires, Argentina.

The University of Copenhagen in Denmark is a very unique place. Apart from being one of the oldest universities in Scandinavia, it is also one of the top universities in the world. So far, 39 Nobel laureates have been affiliated with the University and it sports a spectacular center for healthy aging which hosts the Biology of Aging lab. In September 2021 the University of Copenhagen hosted the 8th annual Aging Research and Drug Discovery (ARDD) meeting.

This year’s ARDD meeting, held at the Ceremonial Hall of the University, was the largest conference on aging and biopharma in the world for the second consecutive year.

The conference, which took place from August 31 to September 3, brought together leaders in the field of longevity research with the focus on aging research, drug discovery and biomarker development. Those who regularly read my articles know that I believe that aging research is the emerging trend in the biopharmaceutical industry. The field is well and truly emerging and ARDD is one of the first conferences to credibly bring together pharmaceutical companies, startups, clinicians, venture capital firms, and representatives from academia to the same table.

The first ARDD meeting was held in 2014 at Basil, Switzerland. Back then, the meeting was known as the Aging Forum and was part of the MipTec and Basel Life congresses. From its inception, the conference was intended to bring together the pharmaceutical industry, leading academics, investors, and startups while maintaining a very high level of scientific credibility, while focusing on the translational potential.

Full Story: